SEARCH

PTAB.US: Decisions of PTAB Patent Trial and Appeal Board Updated Daily.

Monday, March 22, 2010

REVERSED

1600 Biotechnology and Organic Chemistry
Ex Parte Grawe et al SPIEGEL 103(a) BAYER SCHERING PHARMA AG MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Ex Parte Mahant et al ADAMS 103(a) FISH & ASSOCIATES, PC

Ex Parte Mahant et al ADAMS 103(a) FISH & ASSOCIATES, PC

1700 Chemical & Materials Engineering
Ex Parte Kim et al TIMM 102(b)/103(a) ROBERT E. BUSHNELL & LAW FIRM

Ex Parte Rodrigues et al KRATZ 102(b)/103(a) AKZO NOBEL INC.

Ex Parte Bakke HASTINGS 103(a) non-statutory obviousness-type double patenting CABOT CORPORATION

2100 Computer Architecture and Software

Ex Parte Francis et al DANG 101/103(a) U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND

Ex Parte Murray et al BLANKENSHIP 103(a) HOWARD & HOWARD ATTORNEYS PLLC

3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
Ex Parte Amano et al MOHANTY 102(b)/112(1)/112(2) 37 C.F.R. § 41.50(b) KATTEN MUCHIN ZAVIS ROSENMAN

3700 Mechanical Engineering, Manufacturing, and Products & Design
Ex Parte Perini KERINS 103(a) McGLEW & TUTTLE, P.C.

See In re Keller, 642 F.2d 413 (CCPA 1981); In re Merck & Co., 800 F.2d 1091 (Fed. Cir. 1986) (nonobviousness can not be established by attacking references individually where rejections are based on combinations of references).


Keller, In re, 642 F.2d 413, 208 USPQ 871 (CCPA 1981) . . . . . . . . . . . . . . 707.07(f), 2145

Merck & Co., Inc., In re, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986) . . . . . . . .707.07(f), 716.02, 2143.02, 2144.08, 2144.09, 2145

AFFIRMED-IN-PART

1600 Biotechnology and Organic Chemistry
Ex Parte Jones et al PRATS 103(a) OSHA LIANG/MI

2100 Computer Architecture and Software

Ex Parte Saklecha et al THOMAS 102(e) STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Ex Parte Iliff DANG 101/112(1)/102(b)/103(a) KNOBBE MARTENS OLSON & BEAR LLP

3600 Transportation, Construction, Electronic Commerce, Agriculture, National Security, and License & Review
Ex Parte Maughan et al CRAWFORD 112(2)/102(b)/103(a) Siemens Corporation

No comments :